Discontinued — last reported Q4 '25
Year-over-year, this metric grew by 103.1%, from $103.17M to $209.56M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -16.9% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.58B | -$1.18M | $119.55M | $0.00 | $0.00 | $190.32M | $239.39M | $99.27M | $0.00 | $147.39M | $1.99B | $0.00 | $0.00 | $0.00 | $117.51M | $103.17M | $945.00K | $829.13M | $0.00 | $209.56M |
| QoQ Change | — | -100.1% | >999% | -100.0% | — | — | +25.8% | -58.5% | -100.0% | — | >999% | -100.0% | — | — | — | -12.2% | -99.1% | >999% | -100.0% | — |
| YoY Change | — | — | — | — | -100.0% | >999% | +100.2% | — | — | -22.6% | +731.8% | -100.0% | — | -100.0% | -94.1% | — | — | — | -100.0% | +103.1% |